Kymera Therapeutics, Inc. (KYMR) stock
KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30215% above fair value
$115.31−4.08 (-3.42%)
Close on Nov 20, 2026Market cap $9.84BP/E –Yield –
Kymera Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Kymera Therapeutics's free cash flow for the twelve months ending Sep 30, 2026 was -$288.89M. For fiscal 2025 it was -$234.34M. The highest annual figure on record is $79.03M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$234.34M | – |
| FY2024 | Dec 31, 2024 | -$207.34M | – |
| FY2023 | Dec 31, 2023 | -$137.31M | – |
| FY2022 | Dec 31, 2022 | -$155.92M | – |
| FY2021 | Dec 31, 2021 | -$130.54M | -265.2% |
| FY2020 | Dec 31, 2020 | $79.03M | +354.9% |
| FY2019 | Dec 31, 2019 | $17.37M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$78.23M | – |
| Q2 FY2026 | Jun 30, 2026 | -$54.54M | – |
| Q1 FY2026 | Mar 31, 2026 | -$89.27M | – |
| Q4 FY2025 | Dec 31, 2025 | -$66.85M | – |
| Q3 FY2025 | Sep 30, 2025 | -$27.29M | – |
| Q2 FY2025 | Jun 30, 2025 | -$60.58M | – |
| Q1 FY2025 | Mar 31, 2025 | -$79.62M | – |
| Q4 FY2024 | Dec 31, 2024 | -$62.72M | – |
| Q3 FY2024 | Sep 30, 2024 | -$50.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$47.63M | – |
| Q1 FY2024 | Mar 31, 2024 | -$46.99M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.58M | – |
| Q3 FY2023 | Sep 30, 2023 | -$39.73M | – |
| Q2 FY2023 | Jun 30, 2023 | -$46.02M | – |
| Q1 FY2023 | Mar 31, 2023 | -$47.98M | – |
| Q4 FY2022 | Dec 31, 2022 | -$39.91M | – |
| Q3 FY2022 | Sep 30, 2022 | -$35.52M | – |
| Q2 FY2022 | Jun 30, 2022 | -$39.72M | – |
| Q1 FY2022 | Mar 31, 2022 | -$40.78M | – |
| Q4 FY2021 | Dec 31, 2021 | -$38.85M | – |
| Q3 FY2021 | Sep 30, 2021 | -$37.57M | -129.1% |
| Q2 FY2021 | Jun 30, 2021 | -$31.14M | – |
| Q1 FY2021 | Mar 31, 2021 | -$22.99M | – |
| Q4 FY2020 | Dec 31, 2020 | -$21.51M | – |
| Q3 FY2020 | Sep 30, 2020 | $129.26M | – |
| Q2 FY2020 | Jun 30, 2020 | -$15.27M | – |
| Q1 FY2020 | Mar 31, 2020 | -$13.45M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.00M | – |
See a number that looks wrong?